The Modeled Lifetime Cost-Effectiveness of Published Adherence-Improving Interventions for Antihypertensive and Lipid-Lowering Medications

被引:30
作者
Chapman, Richard H. [1 ]
Kowal, Stacey L. [1 ]
Cherry, Spencer B. [1 ]
Ferrufino, Cheryl P. [1 ]
Roberts, Craig S. [2 ]
Chen, Linda [2 ]
机构
[1] IMS Hlth, US Hlth Econ & Outcomes Res, Falls Church, VA 22046 USA
[2] Pfizer Inc, New York, NY USA
关键词
improving adherence; cost-effectiveness; literature review; adherence intervention; antihypertensive; lipid-lowering; cardiovascular disease; RANDOMIZED CONTROLLED-TRIAL; BLOOD-PRESSURE CONTROL; LONG-TERM ADHERENCE; HYPERTENSIVE PATIENTS; MYOCARDIAL-INFARCTION; PATIENT COMPLIANCE; STATIN TREATMENT; DRUG-THERAPY; PERSISTENCE; PROGRAM;
D O I
10.1111/j.1524-4733.2010.00774.x
中图分类号
F [经济];
学科分类号
020101 [政治经济学];
摘要
Objective: We sought to compare the cost-effectiveness of different interventions that have been shown to improve adherence with antihypertensive and lipid-lowering therapy, by combining a burden of nonadherence model framework with literature-based data on adherence-improving interventions. Methods: MEDLINE was reviewed for studies that evaluated >= 1 adherence intervention compared with a control, used an adherence measure other than self-report, and followed patients for >= 6 months. Effectiveness was assessed as Relative Improvement, ratio of adherence with an intervention versus control. Costs, standardized to 12 months and adjusted to 2007 US$, and effectiveness estimates for each intervention were entered into a previously published model designed to measure the burden of nonadherence with antihypertensive and lipid-lowering medications, in a hypertensive population. Outputs included direct medical costs and incremental costs per quality-adjusted life-year (QALY) gained. Results: After screening, 23 eligible adherence-improving interventions were identified from 18 studies. Relative Improvement ranged from 1.13 to 3.60. After eliminating more costly/less effective interventions, two remained. Self-monitoring, reminders, and educational materials incurred total health-care costs of $17,520, and compared with no adherence intervention, had an incremental cost-effectiveness ratio (ICER) of $4984 per QALY gained. Pharmacist/nurse management incurred total health-care costs of $17,896, and versus self-monitoring, reminders, and education had an ICER of $6358 per QALY gained. Conclusions: Of published interventions shown to improve adherence, reminders and educational materials, and a pharmacist/nurse management program, appear to be cost-effective and should be considered before other interventions. Understanding relative cost-effectiveness of adherence interventions may guide design and implementation of efficient adherence-improving programs.
引用
收藏
页码:685 / 694
页数:10
相关论文
共 44 条
[1]
Ali Farzad, 2003, Can J Clin Pharmacol, V10, P101
[2]
[Anonymous], 1996, COST EFFECTIVENESS H, DOI DOI 10.1093/OSO/9780195108248.001.0001
[3]
[Anonymous], AM J MED
[4]
[Anonymous], ADH LONG TERM THER E
[5]
Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy [J].
Benner, Joshua S. ;
Chapman, Richard H. ;
Petrilla, Allison A. ;
Tang, Simon S. K. ;
Rosenberg, Noah ;
Schwartz, J. Sanford .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (16) :1471-1477
[6]
Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy [J].
Benner, JS ;
Pollack, MF ;
Smith, TW ;
Bullano, MF ;
Willey, VJ ;
Williams, SA .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (14) :1468-1475
[7]
Long-term persistence in use of statin therapy in elderly patients [J].
Benner, JS ;
Glynn, RJ ;
Mogun, H ;
Neumann, PJ ;
Weinstein, MC ;
Avorn, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (04) :455-461
[8]
SUSTAINED IMPROVEMENT IN DRUG DOCUMENTATION, COMPLIANCE, AND DISEASE-CONTROL - A 4-YEAR ANALYSIS OF AN AMBULATORY CARE MODEL [J].
BOND, CA ;
MONSON, R .
ARCHIVES OF INTERNAL MEDICINE, 1984, 144 (06) :1159-1162
[9]
Cost effectiveness of an adherence-improving programme in hypertensive patients [J].
Brunenberg, Danielle E. M. ;
Wetzels, Gwenn E. C. ;
Nelemans, Patricia J. ;
Dirksen, Carmen D. ;
Severens, Johan L. ;
Stoffers, Henri E. J. H. ;
Schouten, Jan S. A. G. ;
Prins, Martin H. ;
de Leeuw, Peter W. ;
Joore, Manuela A. .
PHARMACOECONOMICS, 2007, 25 (03) :239-251
[10]
Cardinal H, 2004, CAN J CARDIOL, V20, P417